Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Trademark Approval

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.08
Ask: 2.15
Change: 0.04 (1.90%)
Spread: 0.07 (3.365%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trademark Approval

13 May 2008 06:00

RNS Number : 2381U
Immupharma PLC
13 May 2008
 



For Immediate Release

13 May 2008

ImmuPharma PLC

Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.
 

 

Immupharma has selected the trademark LUPUZOR TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130).

Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.”

 
LUPUZOR TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are expected later this year. LUPUZOR TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR TM may reach the market in around two and a half years’ time, providing substantial revenues for the company.

 

For further information please contact: 

ImmuPharma PLC: 

 

Dimitri Dimitriou, Chief Executive Officer

+44 20 7152 4080

Dr Robert Zimmer, President & Chief Scientific Officer

+ 33 389 32 76 50

Richard Warr, Chairman

+44 20 7152 4080

 

 

Buchanan Communications

+ 44 20 7466 5000

Lisa Baderoon

 

Rebecca Skye Dietrich

 

 

 

Panmure Gordon & Co

 

Andrew Burnett

+44 151 243 0963

For company information, visit www.immupharma.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBKQPBKDNPD
12345678910
Date   Source Headline
31st Jul 20137:00 amRNSFDA GRANTS IMMUPHARMA AMENDED SPA
8th Jul 20138:00 amRNSIMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
5th Jun 20137:00 amRNSHolding(s) in Company
23rd May 201312:29 pmRNSResult of AGM
21st May 20137:00 amRNS£50M Financing Facility - Darwin Strategic
22nd Apr 20137:00 amRNSPosting of Annual Report and AGM Notice
9th Apr 20137:00 amRNSPreliminary Results
28th Feb 20137:01 amRNSImmuPharma Commences Trading on Stuttgart Exchange
28th Jan 20134:03 pmRNSDirector/PDMR Shareholding - Replacement
28th Jan 20131:18 pmRNSDirector/PDMR Shareholding
28th Jan 20139:33 amRNSCNRS Confirms Lupuzor's (TM) Effectiveness
15th Nov 20127:30 amRNSLupuzor Presentation
5th Nov 20127:00 amRNSLupuzor Presentation
3rd Oct 20127:00 amRNSNotification of Major Interest in Shares
26th Sep 20127:01 amRNSFirst Cancer Patients in New Trial Begin Dosing
26th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSNotification of Interim Results
7th Sep 201211:12 amRNSRodman and Renshaw Conference
17th Aug 20129:11 amRNSNotification of Major Interest in Shares
11th Jul 20127:00 amRNSVoted Best Medical Research & Development Company
9th Jul 20127:00 amRNSNew Corporate Website
3rd Jul 20127:00 amRNSAppointment of Joint Broker
23rd May 201212:20 pmRNSAnnual General Meeting: 2012
17th Apr 20127:00 amRNSPosting of Annual Report and AGM Notice
27th Mar 20127:00 amRNSPreliminary Results
29th Feb 20127:00 amRNSAppoints Head of Investor Relations
24th Jan 201212:44 pmRNSDirector's Dealings
3rd Nov 20117:00 amRNSLupuzorT granted approval to start phase III
1st Nov 201110:23 amRNSNotification of Major Interest in Shares
1st Nov 201110:18 amRNSNotification of Major Interest in Shares
21st Oct 20117:00 amRNSImmuPharma regains Lupuzor rights
30th Sep 20117:00 amRNSINTERIM RESULTS ANNOUNCEMENT
23rd Sep 20119:34 amRNSNotification of Interim Results
12th Jul 20112:47 pmRNSNotification of Major Interest in Shares
19th May 201111:19 amRNSResult of Annual General Meeting
5th May 20117:00 amRNSIPP-204106 paper published
26th Apr 20114:38 pmRNSAnnual Report and Accounts & Notice of AGM
5th Apr 20117:00 amRNSPreliminary Results
30th Mar 20117:00 amRNSNotification of Preliminary Results
21st Feb 20117:00 amRNSUpdate on progress of Phase I/IIa Clinical Trial
19th Oct 20101:08 pmRNSUpdate on Phase IIa Clinical Trial
11th Oct 20102:30 pmRNSNotification of major interests in shares
11th Oct 20102:30 pmRNSAdditional Listing and Total Voting Rights
30th Sep 20107:00 amRNSInterim Results
28th Sep 201010:18 amRNSNotification of Interim Results
28th Jun 20107:00 amRNSPresentation at the International Congress
23rd Jun 20107:40 amRNSReplacement of Development release
23rd Jun 20107:00 amRNSCephalon initiates critical steps in development
17th Jun 201012:02 pmRNSResult of AGM
10th Jun 201010:55 amRNSAnnual Report and Accounts
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.